Plus, everything you need to know for the week ahead |
Finimize

👋 Hi John. Here’s what you need to know for the week ahead and what you might've missed last week.

Stumbling Bloc

Europe’s markets have never underperformed Wall Street quite as stridently as they have this year.

Stumbling Bloc

🔍 The focus this week: The eurozone’s long-lost mojo

European markets have been having a tough time keeping up with Wall Street. While the S&P 500 has already posted 25% gains this year, the Eurostoxx is barely in the green – and that’s the widest performance gap on record. In fact, European stocks are trading now at one of the biggest discounts ever, compared to US ones – even accounting for sector differences – and that’s a pretty clear sign of where investors’ heads are at.

And, look, there are some pretty big reasons why: the bloc’s biggest innovation is making more rules, not building the next Nvidia. It’s got a war on its doorstep, the US threatening tariffs, and a slowdown in China that’s hammering its exports. Oh, and Europe still hasn’t cracked its energy crisis. But let’s be real – the biggest problem for its stocks right now is that the region’s economy is running on fumes.

Unfortunately, a turnaround isn’t likely to be right around the corner. Forward-looking indicators like new orders are still dropping while closely tracked business surveys show activity shrinking in both the manufacturing and services sectors. That’s a shame because with Wall Street taking a moment to catch its breath after a tech-fueled bender, Europe might finally have a shot at closing at least some of the gap.

And with expectations as low as they are in Europe, even a small positive surprise could lift spirits. This week’s business and consumer confidence data probably won’t blow anyone away, but “less bad” might be enough to steady the ship. And if inflation plays ball and stays below the central bank’s target, that could pave the way for more aggressive interest rate cuts, which could give the economy a much-needed boost. That just might buy enough time for some longer-term positives to kick in. Of course, that’s a lot of “ifs”...

Walk on the wild side

Ultrasafe investing isn’t for everyone. Some traders are more interested in high-stakes and short-term opportunities.

If that sounds like your cup of tea, you won’t want to miss this session at our Modern Investor Summit: Direxion’s Edward Egilinsky delivering a masterclass on how to navigate high-risk trading.

He'll lay out what’s ahead for the first quarter of 2025, pinpointing the key drivers that could fuel volatility.

You’ll discover how to spot short-term trends, find out about the benefits of advanced hedging and leveraged plays, and uncover the potential of Direxion’s tactical exchange-traded funds.

So grab your free ticket now and be ready for everything 2025 throws at you.

Grab Your Free Ticket

đź“… On the calendar

  • Monday: Germany business sentiment (November). Earnings: Zoom.
  • Tuesday: US consumer confidence (November), US new home sales (October), Federal Reserve meeting minutes. Earnings: CrowdStrike, HP.
  • Wednesday: Germany consumer confidence (December), US durable goods orders (October), US personal income and spending (October), US economic growth revision (third quarter), US core PCE (October).
  • Thursday: Japan inflation (November), Eurozone consumer confidence (November), Germany inflation (November).
  • Friday: China PMIs (November), Japan consumer confidence (November), Eurozone inflation (November).

👀 What you might’ve missed last week

Global

  • Bitcoin’s brushed up against $100,000.


US

  • Nvidia delivered big earnings, but without the fireworks investors hoped for.
  • The US dollar stumbled, opening the door for a new gold bounce.

✍️ What does all this mean?

Nvidia’s earnings were hyped as the year's big showstopper – bigger than the Federal Reserve’s December meeting, some said. And while the AI darling did deliver, the fireworks weren’t quite as dazzling as investors had come to expect. Even with profits doubling from last year, the gains felt like a buzzkill to a market hooked on exponential growth. Two worries stood out for investors: Nvidia’s new Blackwell GPUs might not juice the bottom line as much as hoped, and the company might be leaning too heavily on a handful of big clients (read: cloud providers).

The riskiest of risky assets has been on a tear since the US election, now flitting around the $100,000 mark for the first time. And a few new things are driving the rally. First, there are whispers about a potential new US government role dedicated to digital assets. Second, the top US financial regulator – long viewed as the crypto world’s ultimate party pooper – announced he would step down in January. And third, BlackRock broke new ground in the market – selling options on its iShares Bitcoin Trust ETF.

The US dollar’s been on a tear since September, fueled by expectations of higher tariffs and market bets that a new government agenda could supercharge the US economy that would push inflation higher, and keep the Fed from cutting rates. But last week, the rally took a breather as folks started questioning whether the surge was overdone. That pause gave commodities some breathing room – especially gold, which has struggled under the weight of the strong dollar – which makes it more expensive for foreign buyers.

* Sponsored by BioStem

Medical tech that’s saving lives – and making millions doing it

BioStem (BSEM) is on a mission to improve millions of lives by revolutionizing how we heal wounds. Its products are designed to help patients recover from major surgeries and treat chronic wounds, like diabetic foot ulcers.

And there’s a huge opportunity in that: the diabetic foot ulcer market alone was worth over $4 billion in 2021, and demand for advanced wound care solutions is growing.

BSEM’s allografts drove $82 million in revenue last quarter, so it’s no wonder analysts at Zacks Small-Cap Research raised BSEM’s stock estimate to $32.50.

With cutting-edge regenerative therapies, BSEM continues to push the boundaries of wound care innovation, making it a leader in this fast-growing market.

Want to explore how BSEM is healing the future? Find out more information here.

Learn More

This content is for US investors only, if you are not a US investor please ignore this content. This content is a paid advertisement for BioStem Technologies, Inc from Sideways Frequency and Finimize. This is not Finimize editorial content. Finimize received a fixed fee from Sideways Frequency for producing, hosting and promoting this content via 4 email sends on behalf of BioStem Technologies, Inc, totalling $16,000. Other than the compensation received for this service, Finimize and its principals are not affiliated with either Sideways Frequency or BioStem Technologies, Inc. Finimize and its principals have no ownership in BioStem Technologies, Inc.

The content on this page should not be taken as advice, an endorsement, or a recommendation from Finimize and its principals to buy or sell any security. Finimize and its principals have not evaluated the accuracy of any claims made on this page. Finimize and its principals recommend that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky and capital is at risk. Past performance is not indicative of future results.

When you support our sponsors, you support us. Thanks for that.

If you want your brand featured here, get in touch.

⏸ Want to turn off the Weekly Review? Hit pause

To stop receiving all Finimize emails (including the daily newsletter) Unsubscribe

View in browser

Crafted by Finimize Ltd. | 280 Bishopsgate, London, EC2M 4AG

All content provided by Finimize Ltd. is for informational and educational purposes only and is not meant to represent trade or investment recommendations. You signed up to this mailing list at finimize.com or through one of our partners. © Finimize 2024